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Introduction
EBV was discovered in 1964 by electron microscopy 
of suspension cultures of African Burkitt lymphoma 
cells (Epstein et al., 1964). EBV is a member of Her-
pesviridiae family and is a double stranded DNA virus 
(Martinez and de Gruijl, 2008). It is known as human 
herpesvirus 4 (Odumade et al., 2011). 
EBV is an important agent that affects nearly all 
adults throughout the world (Kreuzer et al., 2013). 
In Turkey, seropositivity rates in adult age are found 
between 70–99.4% (Zeytinoğlu et al., 2005; Ozkan et al., 
2003). Primary EBV infection is usually seen as asymp-
tomatic infection in childhood. Generally, younger chil-
dren are moderately ill, and the severity of primary EBV 
infection in adult increases with age (Odumade et al., 
2011). During primary infection, EBV can cause a wide 
variety of symptoms, depending on the host age and 
immune status, ranging from asymptomatic infection 
to severe infectious mononucleosis (IM) with com-
plications (Ebell, 2004; Gärtner et al., 2003). IM typi-
cally begins with malaise, and followed by fever, sore 
throat, swollen cervical lymph nodes and fatigue. Some 
patients experience an abrupt influenza-like onset, with 
fever, chills, body aches and sore throat (Odumade 
et al., 2011). Cytomegalovirus (CMV), Rubella virus, 
Toxoplasma gondii infections and hematologic malig-
nancies can cause similar symptoms. Therefore differ-
ential diagnosis of these agents is important. 
EBV is intermittently shed from saliva. The main 
route of transmission is orally from person to person 
although transmission via blood products, transplanta-
tion, and sexual transmission were shown (Schooley, 
1995; Woodman et al., 2005). Being commonly trans-
mitted through saliva; acute IM is called “the kissing dis-
ease” (Thompson, 2015). Virus can affect B and T lym-
phocytes, epithelial cells and smooth muscle cells, and 
can cause malign transformation. It is associated with 
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A b s t r a c t
The accurate diagnosis of Epstein-Barr virus (EBV) infections is important, as many other infectious agents or diseases can cause simi-
lar symptoms. In this study, sera of pediatric patients who were suspected to have an EBV infection, were sent to Eskisehir Osmangazi 
University Faculty of Medicine, Department of Clinical Microbiology, and investigated by IFA, ELISA, immunoblotting and Real-time 
PCR. The performances of these tests were compared with IFA. The rates of agreement between ELISA and IFA were found as 100% for 
seronegative, 100% for acute primary infection, 22.2% for late primary infection, 92.1% for past infection. The rates of agreement between 
immunoblotting and IFA were found as 80.8% for seronegative, 68.8% for acute primary infection, 55.6% for late primary infection, 86.6% 
for past infection. The sensitivity of immunoblotting for anti-VCA IgM was identical with ELISA, and higher for anti-VCA IgG, anti-EBNA 
IgG, anti-EA antibodies, while the specificity of immunoblotting for these antibodies were found to be lower. The sensitivity and specifi-
city of Real-time PCR for detection of viremia in acute primary infection were found as 56.25% (9/16) and 97.89% (139/142), respectively. 
The diagnostic methods should be chosen by evaluating the demographic characteristics of patients and laboratory conditions together.
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Burkitt lymphoma, nasopharyngeal carcinoma, post- 
transplantation lymphoproliferative disease, Hodgkin 
and non-Hodgkin lymphoma, gastric carcinoma and 
leiomyosarcoma (Duca et al., 2007).
In immunocompetent individuals, EBV infection 
is controlled by the humoral and cellular immune 
responses, in cooperation with the interferon system. 
EBV reactivation in immunocompetent individuals 
may not cause any specific symptoms. But in immu-
nocompromised individuals such as solid organ or bone 
marrow recipients, and HIV infection, virus reactiva-
tion can cause serious complications (Jacobson and 
LaCasce, 2010).
Formerly, for the diagnosis of acute primary EBV 
infections, peripheral blood smear (atypical lympho-
cytes-Downey cells), monospot and Paul-Bunnell agglu-
tination test could be used, but as these tests are not spe-
cific to the EBV infection and false negativity rates are 
high in children aged under 4 especially in Paul-Bunnell 
test (Horwitz et al., 1981), evaluating specific antibodies 
by Immunofluorescence Assay (IFA), Enzyme Linked 
Immuno Sorbent Assay (ELISA), Immunoblotting and 
searching for DNA by molecular methods are used 
recently. In immunocompromised individuals, evalu-
ating viral DNA by molecular methods should be used 
because of the inefficient antibody response.
In this study, serum samples of pediatric patients 
who were suspected to have an EBV infection were sent 
to Eskisehir Osmangazi University Medicine of Faculty, 
Department of Medical Microbiology, and investiga- 
ted by IFA, ELISA, Immunoblot and Real-time PCR. 
The performances of these tests were compared with 




Design of study. One hundred and seventy-eight 
consecutive samples that were received between Febru-
ary-June 2013 for EBV serology, from pediatric patients 
(median age 72 months; range: 24–216 months; 56.7% 
male, 43.3% female) applied to Eskisehir Osmangazi 
University Medical Faculty with lymphadenopathy, 
pharyngitis, fever, hepatomegaly and/or splenomegaly 
were included in this study. For the control group, 
30 healthy pediatric individuals (median age 78 months; 
range: 24–204 months; 43.3% male, 56.7% female) were 
included. In a total of 208 serum samples, EBV specific 
antibodies were studied by IFA, ELISA, immunoblot-
ting, and EBV DNA was evaluated by Real-time PCR. 
Methods. EBV specific antibodies were evaluated 
by indirect IFA, ELISA and immunoblotting in serum 
samples, and results were interpreted according to the 
manufacturers. Viremia was evaluated by real-time 
PCR in all patients except seronegatives.
IFA. EBV anti-viral capsid antigen (VCA) IgG, 
anti-VCA IgM, anti-early antigen (anti-EA) IgG, anti-
Epstein-Barr nuclear antigen (EBNA) IgG and anti-
VCA IgG avidity tests were evaluated simultaneously 
with commercial IFA kit (Euroimmun AG, Lüebeck, 
Germany). The wells of the slides were prepared from 
human EBV transformed cell lines obtained from 
Burkitt lymphoma patients and the cell lines P3HR1 
expressing VCA, Raji cell expressing EBNA complex, 
and EU-33 expressing EA antigen. The test was studied 
according to the manufacturer’s instructions and the 
slides were evaluated under × 20 and × 40 objectives of 
fluorescent microscope in accordance with the manu-
facturer’s instructions.
ELISA. Anti-VCA IgG, anti-VCA IgM, anti-EBNA 
IgG, anti-EA IgG antibodies and anti-VCA IgG avid-
ity were evaluated by Euroimmun AG, Lüebeck, Ger-
many ELISA kits according to the recommendations 
of manufacturer. For anti-VCA IgG avidity, serum 
samples were studied duplicated one with urea (8 M 
concentration) and one without. At the end of the study, 
relative avidity index was calculated, and values up to 
40 were considered as low avidity (indicating recently 
acquired infection) and those exceeding 60 were con-
sidered as indicative of high avidity. Values between 40 
and 60 were evaluated as grey zone.
Immunoblotting. Euroline anti-EBV profil 2 Immu-
noblot kit (Euroimmun, Germany) was used to detect 
EBV specific anti-VCA IgM, anti-VCA IgG, anti-
EBNA-1 IgM, anti-EBNA-1 IgG, anti-p22 IgM, anti-
p22 IgG, anti-EA IgM and anti-EA IgG antibodies. 
This kit contains test strips coated with parallel lines of 
different antigens. In the case of positivity, the specific 
IgG or IgM antibodies bind to the corresponding anti- 
genic site, and then to detect the antibodies, another 
incubation is performed using an enzyme-labelled anti-
human Ig to create a color change. Test was performed 
and at the end of the study the strips were scanned and 
evaluated by software according to the instructions of 
manufacturer. 
Real-time PCR. EBV Real-time PCR Kit, Exicycler™ 
96 thermal block, ExiCycler 96 Real-time PCR (Bioneer, 
Korea) system were used to detect EBV DNA quantita-
tively in serum samples. DNA isolation was performed 
by ExiPrep viral DNA/RNA extraction kit and device 
(Bioneer, Korea). In PCR stage, lyophilized PCR mix 
was diluted and DNA was added. Then patient samples 
and five standards were loaded to the system. In PCR 
stage the cycle was as following: predenaturation at 95°C 
for 5 min., 45 cycles of denaturation at 95°C for 5 s and 
annealing and detection at 55°C for 5 s. Data were evalu-
ated by ExiDiagnosis (Diagnostic Soft. ver. 1.27.3). 
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Results
EBV infectious serology was evaluated in patient 
(n = 178) and control (n = 30) groups by ELISA and 
immunoblotting tests, and results were compared with 
IFA as the reference method. EBV DNA was searched 
in sera by real-time PCR to evaluate viremia. 
EBV infection stages were determined by IFA 
reference method, according to the EBV diagnosis 
standards (Linde and Falk, 2007). In patient group, 26 
(14.6%) seronegativity, 16 (9.0%) acute primary infec-
tion, 9 (5.1%) late primary infection, 127 (71.3%) past 
infection were determined by IFA. In control group, 
25 (83.4%) past infection, 4 (13.3%) seronegativity and 
1 (3.3%) late primary infection stages were determined. 
EBV infection stages were also determined by ELISA 
and immunoblotting methods, and these results were 
compared with IFA results (Table I and Table II).
In patient group, ELISA and IFA concordance was 
as 100% for seronegativity, 100% for acute primary 
infection, 22.2% for late primary infection, 92.1% for 
past infection. Immunoblotting and IFA concordance 
was as 80.8% for seronegativity, 68.8% for acute pri-
mary infection, 55.6% for late primary infection, 86.6% 
for past infection. In control group, the concordance of 
ELISA and immunoblotting with IFA were as 100%.
When considering specific antibodies, the results 
obtained by ELISA and immunoblotting were com-
pared with IFA results, and the sensitivities, specifici-
ties, positive predictive values and negative predictive 
values of methods were evaluated (Table III and IV).
The sensitivity of immunoblotting method was 
found similar with ELISA method for anti-VCA IgM, 
and was higher than ELISA for the other three antibod-
ies, but the specificity was lower than ELISA for all four 
antibodies. Table V and Table VI show the PCR results 
and viral loads according to the infection stages, respec-
tively. DNA was not detected in the control group. The 
sensitivity of real-time PCR in detecting viremia dur-
ing acute primary infection is 56.25% (9/16), and the 
specificity is 97.89% (139/142).
Discussion
In immunocompetent individuals, the main aim to 
evaluate serological antibodies is to diagnose acute pri-
mary infection (Gärtner et al., 2003). Three antibodies 
are essential for the detection of infection stage in 
SN 26 – – 2 28
API – 16 5 1 22
LPI – – 2 7 9
Past – – 2 117 119
Total 26 16 9 127 178
Table I
Comparison of stages determined by ELISA and IFA
in patient group.
SN = seronegative, API = acute primary infection,






SN 21 – – 1 22
API – 11 2 2 15
LPI 2 5 5 14 26
Past 3 – 2 110 115
Total 26 16 9 127 178
Table II
Comparison of stages determined by immunoblotting
and IFA in patient group.
IB = immunoblotting, SN = seronegative, API = acute primary infection,






Anti-VCA IgM Pos. 20 7 83.33 95.45 74.07 97.35 0.748
 Neg. 4 147     (Substantial agreement)
Anti-VCA IgG Pos. 145 1 96.03 96.30 99.32 81.25 0.858
 Neg. 6 26     (Almost perfect agreement)
Anti-EBNA IgG Pos. 114 5 91.20 90.57 95.80 81.36 0.792
 Neg. 11 48     (Substantial agreement)
Anti-EA IgG Pos. 6 2 26.09 98.71 75 90 0.343
 Neg. 17 153     (Fair agreement)
Table III
Comparison of antibody results obtained by ELISA with IFA results in patient group.
Pos. = positive, Neg. = negative, sens. = sensitivity, spec. = specificity, PPV = positive predictive value, NPV =  negative predictive value
ELISA
IFA ELISA
Neg. PPVSpec.Sens. NPV Kappa valuePos.
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immunocompetent patients: anti-VCA IgM, anti VCA 
IgG and anti-EBNA-1 IgG. Presence of anti-VCA IgM 
and anti-VCA IgG, absence of anti-EBNA IgG means 
acute primary infection, and presence of anti-VCA IgG 
and anti-EBNA with absence of anti-VCA IgM means 
past infection (De Paschale and Clerici, 2012). Isolated 
anti-VCA IgG positivity, isolated anti-EBNA positivity 
and the presence of all three parameters are difficult to 
interpret. In these situations, to evaluate IgM and IgG 
antibodies with immunoblotting, anti-VCA IgG avid-
ity test, anti-EA/D antibodies and to investigate viral 
genome with molecular methods are recommended 
(De Paschale and Clerici, 2012). In many instances dif-
ferent methods can be simultaneously used to detect the 
correct infection stage.
In this study, we compared the results of different 
methods with gold standard IFA test. In our patient 
group, the ratio of acute primary infection stage was 
as 9.0%, and late primary infection consisted of 5.1% 
of patients. All of the acute primary infection patients 
(n:16) were also interpreted as acute primary infection 
by ELISA method. But six other patients were inter-
preted as acute primary infection by ELISA although 
five of them were late primary, and one was past infec-
tion by IFA. The compliance value of ELISA and IFA 
was as 100% for seronegativity and acute primary infec-
tion, and 92.1% for past infection, but this value was 
low for late primary infection. Only two of 9 late pri-
mary infections were interpreted correctly by ELISA. 
Five patients were interpreted as acute primary infec-
tion, and 2 were as past infection. 
By ELISA, four specific antibodies are evaluated (anti 
VCA IgM, anti VCA IgG, anti EBNA IgG and anti EA 
IgG). When solely anti VCA IgG is positive, it is recom-
IFA Seronegative – 6 20 26
 Acute primary infection 9 7 – 16
 Late primary infection 2 7 – 9
 Past infection 1 126 – 127
ELISA Seronegative – 8 20 28
 Acute primary infection 11 11 – 22
 Late primary infection – 9 – 9
 Past infection 1 118 – 119
IB Seronegative – 2 20 22
 Acute primary infection 7 8 – 15
 Late primary infection 5 21 – 26
 Past infection – 115 – 115
Total  12 146 20 178
Table V
Evaluation of real-time PCR results based on infectious stages by IFA, ELISA
and immunblotting methods in patient group.
IB = immunoblotting, N/A = not applied
Real-Time PCR
Detected Not detected N/A Total
Anti-VCA IgM Pos. 20 15 83.33 90.26 57.14 97.20 0,617
 Neg. 4 139     (Substantial agreement)
Anti-VCA IgG Pos. 150 6 99.34 77.78 96.15 95.45 0.835
 Neg. 1 21     (Almost perfect agreement)
Anti-EBNA IgG Pos. 120 15 96 71.70 88.89 88.37 0.716
 Neg. 5 38     (Substantial agreement)
Anti-EA IgG Pos. 17 25 73.91 83.87 40.48 95.59 0.427
 Neg. 6 130     (Moderate agreement)
Table IV
Comparison of antibody results obtained by immunoblotting with IFA results in patient group.
IB = immunoblotting, Pos. = positive, Neg. = negative, sens. = sensitivity, spec. = specificity, PPV = positive predictive value,
NPV = negative predictive value
IB
IFA IMMUNOBLOTTING
Neg. PPVSpec.Sens. NPV Kappa valuePos.
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men ded to test anti VCA IgG avidity to distinguish 
late primary infection from past infection without anti 
EBNA. The avidity testing of VCA IgG may also help 
to resolve cases in which VCA IgM persists for a long 
term (Bauer, 2001). In our study, all of the patients with 
solely anti VCA IgG positivity (n = 9) had low avidity 
index values, therefore they were interpreted as late pri-
mary infection by ELISA. Two of them were interpreted 
as late primary infection, and seven were past infection 
by IFA. Four of these 9 patients were also solely positive 
for anti VCA IgG by IFA. They were interpreted accord-
ing to their avidity results. In the literature, the pres-
ence of isolated anti VCA IgG profile occurs in 2–8% 
of immunocompetent patients tested for EBV (Klutts 
et al., 2009; De Paschale et al., 2009), and most of these 
cases are thought to correspond to past infections. In 
our patient group, isolated anti VCA IgG positivity was 
seen in 10  (5.6%) patients by standard method IFA. 
Two patients were diagnosed as late primary infec-
tion due to their avidity index values. Eight patients 
were interpreted as past infections. Seven of these eight 
patients were positive for anti-EBNA IgG, and negative 
for anti-EBNA IgM by immunoblotting, so they were 
interpreted as past infection. One of them had anti-
EBNA IgM but not anti-EBNA IgG and was interpreted 
as late primary infection. Isolated anti-VCA IgG can be 
found in patients with past infection as non-appearance 
or loss of EBNA-1 IgG, and in patients with acute infec-
tion with the delayed appearance or early loss of anti-
VCA IgM (De Paschale et al., 2009). It is reported that 
anti-VCA IgM may appear 1–2 weeks after anti-VCA 
IgG or lasts for a short time, or anti-VCA IgM can be 
at low concentrations therefore it cannot be detected. 
Furthermore, some patients are negative for anti-EBNA 
IgG after recovery (De Paschale et al., 2009; Bauer, 
1995). In a study that evaluated EBV serological mark-
ers of 2422 patients with suspected EBV infection by 
ELISA, isolated anti-VCA IgG positivity rate is found as 
7% (De Paschale et al., 2009). In some instances, second 
sampling of blood is preferred to correctly diagnose 
the infection stage, but especially in children it may be 
difficult. It is important to correctly diagnose the stage 
in one sample. It may be possible by evaluating the anti-
VCA IgG avidity simultaneously. 
As mentioned above, all of the acute primary infec-
tion cases were diagnosed correctly by ELISA. Kreuzer 
et al., (2013) compared two different ELISA assays with 
IFA method in 537 samples and reported the agreement 
values of assays as 100% for acute infection. The agree-
ment values in seronegativity and past infection were 
as 89.7–100% and 98.1–99.1%, respectively. Schaade 
et al. (2001) compared the performances of EBV spe-
cific ELISA with indirect immunofluorescent reference 
method in 66 children patients and concluded that the 
ELISA system used were suitable for the diagnosis of 
seronegativity and acute EBV infection by that system 
could not determine recent primary and past infec-
tions correctly and had a high rate of indeterminate 
results. Also, they suggested that the ELISA system used 
was not applicable to the diagnosis of reactivated EBV 
infections. Devanthéry and Meylan (2010) evaluated 
EBV infection stages of 387 serum samples by three 
different methods and determined a consensus stage. 
They reported ELISA/consensus concordance as 85% 
(329/387). In 85 samples the consensus stage was acute 
infection, but ELISA could detect 67 of them correctly. 
In 18 samples the ELISA could give indeterminate or 
grey zone results. On the other hand, all of the acute 
infection results determined by ELISA were evaluated 
as acute infection by consensus. The sensitivity and 
specificity of ELISA kits are critical in stage evalua-
tion. Especially the sensitivity of anti-VCA IgM is very 
important to detect acute infections. The EBV-specific 
tests differ in the substrates or antigens used, and the 
interpretation criteria are different among various man-
ufacturers (Hess, 2004). The reference method IFA usu-
ally uses EBV-transformed B cell lines from Burkitt’s 
lymphoma patients; on the contrary, most ELISA kits 
use purified native or recombinant antigens (Gärtner, 
et al., 2003; De Paschale and Clerici, 2012). The most 
important thing in determining the correct stage is to 
choose high quality kits. ELISA is preferred in many 
laboratories as it is practical. As these assays can be 
automated, they can improve speed and efficiency of 
EBV testing, especially in high-volume laboratories.
When we compared immunoblotting stage results 
with IFA, we realized that the concordance rates were 
low. Five of 16 (31.2%) acute primary patients were 
evaluated as late primary infection. The ages of these 
   92 Past Past Late primary
   96.9 Acute Acute Late primary
  283 Acute Acute Acute
 1120 Acute Acute Acute
 2470 Acute Acute Acute
 5440 Acute Acute Late primary
 6450 Acute Acute Late primary
 6450 Late primary Acute Late primary
 8550 Acute Acute Acute
 8730 Late primary Acute Acute
10300 Acute Acute Acute
16700 Acute Acute Acute
Table VI
Distribution of real-time PCR positive results on the basis
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patients were 3, 3, 5, 10, and 12. Three of these patients 
were positive by PCR (96.9, 5440, 6450 copies/ml 
respectively) and all of these five patients were diag-
nosed as acute primary infection by ELISA. Immuno-
blotting method in our study uses recombinant anti-
gens (VCA p19, EBNA-1, p22, EA-D) and one native 
purified antigen by chromatography (VCA gp125). 
Recombinant EBV specific antigens are accepted to 
be superior to lysate antigens, because they are not 
influenced by potential anti-cellular antibodies (Bauer, 
2001; Gärtner et al., 2001). Basically, infection stages 
can be evaluated according to anti-VCA IgM, anti-VCA 
IgG, anti-EBNA-1 IgG, anti-EA-D IgG and anti-p22 
IgG. This method is highly specific and used mostly as 
a confirmatory method (Hess, 2004). 
In our study, with the use of anti-VCA IgG avid-
ity, we defined late primary infection stage by ELISA 
and IFA. To make accurate comparisons, we defined 
stages compatible with late primary infection by evalu-
ating the antibodies detected by immunoblotting. As 
it is reported in the literature, during convalescence, 
anti-VCA IgM antibodies decrease, while anti VCA IgG 
antibodies rise and persist for life. Between the third 
and sixth months, anti-VCA IgM antibodies disap-
pear but anti-EBNA-1 IgG antibodies become detect-
able. Therefore, anti-VCA IgM, anti-VCA IgG and 
anti-EBNA IgG may be present simultaneously in late 
primary infection and reactivation (Nystad and Myr-
mel, 2007). We also evaluated the anti-EBNA-1 IgM to 
be able to make correct comments on stages of infec-
tions. It is reported as an indicator of recent primary 
infection, and it is positive for 2–4 months after pri-
mary infection. Although there are a few commercially 
available anti-EBNA-IgM ELISA kits, anti-EBNA IgM 
is not used in routine diagnosis of EBV infections. In 
our study, we could be able to evaluate anti-EBNA IgM 
by immunoblotting IgM strips. 26 patients and 1 indi-
vidual of the control group were evaluated as late pri-
mary infection. 20 of them were positive for anti-VCA 
IgM, anti-VCA IgG and anti-EBNA IgG, and in 10 anti-
EBNA IgM was positive. In 7 samples, anti-VCA IgM 
and anti-EBNA IgG were negative but anti-VCA IgG 
was positive. According to their ages and/or anti-EBNA 
IgM results they were evaluated as late primary infec-
tion. By immunoblotting, some of the results were dif-
ficult to interpret. In routine diagnosis additional tests 
should be performed to diagnose the correct stage. But 
in our study, we aimed to evaluate the sufficiency of 
the tests alone. Although immunoblotting is suggested 
as a confirmatory test (Hess, 2004), we had some seri-
ous problems especially when anti VCA IgM, IgG and 
anti-EBNA IgG were simultaneously or when only anti 
VCA IgG was positive. Maybe we should report these 
results as “not determined” but we evaluated them as 
“late primary infection” and this may be our limitation. 
We also aimed to measure the agreement of dif-
ferent methods in detecting the specific antibodies 
correctly as well as the correct staging, and evalu-
ated sensitivity and specificity values. To interpret the 
degree of agreement, the guidelines reported by Cohen 
and Viera were used: Kappa value between 0.01–0.20 
slight agreement, 0.21–0.40 fair agreement, 0.41–0.60 
moderate agreement, 0.61–0.80 substantial agreement, 
0.81–0.99 almost perfect agreement (Cohen, 1960; 
Viera and Garrett, 2005). According to these criteria, 
ELISA method had substantial or almost perfect agree-
ment values for anti VCA IgM, IgG and anti-EBNA IgG. 
But this value was very low for anti-EA IgG. There-
fore, we suggest that in immunocompetent patients, it 
is appropriate and sufficient to evaluate the infection 
stage by these three antibodies but not anti-EA IgG. 
Likewise, the agreement value of anti-EA IgG of immu-
noblotting method was low as moderate agreement. As 
immunoblotting is recommended as a confirmatory 
method, this low value is disappointing. 
In the literature, anti-EA IgG is reported positive 
in approximately 85% of patients with acute infection, 
but in some cases, it can still be positive for years after 
acute primary infection. During reactivation or naso-
pharyngeal carcinoma, high titers of anti-EA IgG are 
seen (de Paschale and Clerici, 2012). It is also reported 
that, IgG reactivity against EA can be seen in all phases 
of infection, although it is predominantly seen during 
lytic infection (Nystad and Myrmel, 2007). Since an 
increase in the titer of anti-EA IgG can be considered as 
a marker of reactivation, it is suggested to evaluate anti-
EA IgG only if serial sampling is possible (De Paschale 
and Clerici, 2012). In a study by Altuglu et al., (2007), 
they reported the kappa value of anti-EA IgG of the 
same immunoblotting system as 0.67 (substantial 
agreement). But this value was as 0.20 for anti-EA IgG 
with automated bead assay. Klutts et al., (2009) evalu-
ated specific EBV antibodies and determined all pos-
sible phases that may occur. They reported that except 
for the relatively small number of primary acute infec-
tion patients, anti EA IgG was of little utility. Also Hess 
(2004) reported the positivity rate of anti-EA IgG in 
primary infection as 60–80% and suggested that in 20% 
of healthy individuals it is present. In this literature it is 
reported that EA specific serological parameters are not 
helpful to confirm any stage specific diagnosis. 
In addition to the comparison of the methods in 
evaluating individual parameters, sensitivity and speci-
ficity values were also compared. The sensitivity of 
these two methods was the same for anti VCA IgM, and 
immunoblotting had slightly high values for anti VCA 
IgG and anti EBNA IgG. But the sensitivity perfor-
mance of immunoblotting was significantly better for 
anti EA IgG. When we considered the specificity values, 
immunoblotting method had lower values. Immuno-
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blotting assays are considered to have high specificity 
for EBV serology but unfortunately we had lower values 
than ELISA, especially for anti EBNA IgG (false posi-
tive results; 15/53). This means that, anti EBNA nega-
tive acute primary infection serologic profiles could 
be diagnosed as past infection, according to the anti 
EBNA IgG positivity. The IFA method is labor-inten-
sive and requires experience. To prevent or minimal-
ize the false positive or negative results, the slides were 
evaluated by two different researchers, and confirmed 
by a specialist in this topic. Besides, to make accurate 
comparison and to eliminate the differences between 
manufacturers, we used ELISA, IFA and immunoblot-
ting kits from the same manufacturer. The antigens 
used by IFA for anti-VCA antibodies were antigen 
expressing P3HR1 cells and, native gp125 and recom-
binant p19 antigen. The antigens used by ELISA and 
immunoblotting were similar. For anti-EBNA IgG and 
anti-EA, ELISA and immunoblotting used recombinant 
antigens, but IFA used cells expressing EA antigen and 
Raji cells expressing EBNA.
In the active phase of the infection, EBV DNA is pre-
sent in plasma or serum samples. In addition to active 
infection, EBV DNA viremia is present in reactivation, 
EBV associated malignancies, and posttransplant lym-
phoproliferative disease. Our study group consisted of 
pediatric patients; therefore the most common causes 
of the EBV serologic tests in routine practice were to 
diagnose the acute primary infection, and to exclude 
EBV infection in patients with lymphadenopathy. 
In our study, we detected EBV DNA in 9 of 16 acute 
primary infection patients. Therefore, we determined 
the sensitivity in active infection as 56.25%. EBV DNA 
was positive in 2 (viral loads were 6450 and 8730 cop-
ies/ml) of 9 late primary and 1 (viral load 92 copies/
ml) of 127 past infection patients. The latter patient was 
a 3-year old child with classic triad of EBV infection as 
sore throat, cervical lymphadenopathy and fever. Inter-
estingly, the stage determined by immunoblotting was 
as late primary infection with anti VCA IgM positivity. 
This finding made us think that whether ELISA and 
IFA methods could not detect the anti VCA IgM. But 
as IFA was considered as the gold standard test for the 
EBV infections, we suggested the anti-VCA IgM of 
immunoblotting as false positive. In routine practice, 
real time PCR would not be performed for this patient 
as it was considered as past infection. Detecting viremia 
by molecular methods is necessary for immunosup-
pressed individuals, as serological assays are insuffi-
cient due to their deficiencies in generating antibodies. 
Therefore, in immunosuppressed patients, detection of 
viral load by PCR is recommended (Hess, 2004). We 
suggest that the duration of viremia and the viral load 
may vary between patients, as we could not detect in 
some of acute primary patients but detected in late pri-
mary stage. Our positivity rate of EBV DNA in acute 
primary infection was lower than studies reported pre-
viously. Chan et al. (2001) and Gartzonika et al. (2012) 
reported the sensitivity of PCR in acute infections as 
80% and 93.5%, respectively. The PCR system we used 
is a closed system that prevents the contamination, 
and the range of detection of the kit is 10–1010 copies/
reaction. In the literature, it is reported that, in immu-
nocompetent infectious mononucleosis patients, EBV 
DNA is detectable in serum for only approximately 
seven days after onset of symptoms (Fafi-Kremer et al., 
2005). In addition, Berth et al. (2011) reports that EBV 
DNA can be undetectable while the serological profile 
can be acute EBV infection. Therefore, we commented 
that the low sensitivity rate could be due to the short 
duration of viremia in our patients. 
In our study, we aimed to evaluate the performances 
of different diagnostic methods on determining the 
infection stages and detecting the specific antibodies in 
serum samples of patients with suspicious of EBV infec-
tions. But as a limitation of our study, we did not evalu-
ate the anti-CMV IgM and IgG antibodies to exclude 
cross reactivation on anti VCA IgM positive samples. 
In conclusion, IFA is the gold standard test for the 
diagnosis of EBV infections, but the most important 
disadvantages are the high cost and the requirement of 
experienced staff. The compliance of ELISA with IFA 
is high, and this method provides advantages in terms 
of ease of use as it is practical and can be automated. 
Although immunoblotting is recommended as a con-
firmatory test in EBV diagnosis, high false positivity 
rates should be kept in mind. Especially in immuno-
compromised patients that serological methods are 
insufficient, real-time PCR is recommended to detect 
viremia. The most suitable diagnostic method should 
be decided according to the demographic character-
istics of patient groups, experience of the staff, fin 
ancial facilities, working conditions of the laboratory, 
and when necessary the correct conclusion should be 
achieved using more than one diagnostic method as 
a test battery. 
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